Elritercept
Based on 1 Customer Validation
Elritercept (KER-050) is a modified activin type IIA receptor ligand trap. Elritercept binds to and neutralizes TGF-β superfamily ligands, including TGF-β, activins (activins), GDF8, GDF11 , and GDFs, blocking ActRIIa-mediated signaling, inhibiting SMAD2/3 signaling, and rebalancing signaling. Elritercept can be used in research on myelodysplastic syndromes, myelofibrosis, MDS/MF-associated anemia, and acute myeloid leukemia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 97.868%
- CAS. Nr.: 2727114-26-1
-
Speicherung:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Biologische Aktivität
Beschreibung
Species Reactivity
Human
|
TGF-β |
activins |
GDF8 |
GDF11 |
ActRIIa |
Smad2 |
Smad3 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C1498-GFP mouse AML cells
-
Concentration:400 ng/mL (alone and in combination with ActA 100 ng/mL)
-
Incubation Time:overnight pre-incubation; 4 h (migration assessment)
-
Result:Migratory ability of the AML cells was significantly reduced.
AML cells pre-incubated with an ActA-containing combination showed significantly reduced migration compared with ActA-pre-incubated cells.
ActA-induced migration of AML cells was inhibited.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 9 weeks old)[6]
-
Dosage:10 mg/kg
-
Administration:intraperitoneal (IP) injection; twice weekly; 3 weeks
-
Result:Increased RBCs (+21%), hemoglobin (+16%), hematocrit (+16%), and reticulocytes (+21%) compared to vehicle control.
Increased BM osteoblast (+81%) and BMSC (+23%) populations compared to vehicle control.
Did not change CFU-F numbers compared to vehicle control.
Increased CFU-ALP (+52%) compared to vehicle control.
Increased CFU-Ob (+36%) compared to vehicle control.
Did not change CFU-ADP numbers compared to vehicle control.
Increased osteoblast marker gene expression, osterix (Sp7) and osteocalcin (Ocn), with no changes in adipocyte marker gene expression compared to vehicle control.
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
FPIA_[PROTEIN]2-FC
Anwendung
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Activin A Protein, Human (Biotinylated, HEK293, Avi, HY-P703994) can bind Elritercept. The EC50 for this effect is 9.269 ng/mL.
Chemical Information
-
CAS. Nr. 2727114-26-1
-
Appearance Liquid
-
Color Colorless to light yellow
-
Synonyms
KER-050
-
Versand
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Elritercept Related Classifications
HY-P990720 Related Classifications
Powered by Bioz